PA
ENGN icon

Perceptive Advisors’s enGene Therapeutics ENGN Stock Holding History

Perceptive Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.34M Sell
4,822,169
-1,005,337
-17% -$4.1M 0.13% 83
2026
Q1 		$39.7M Sell
5,827,506
-41,570
-0.7% -$370K 0.78% 29
2025
Q4 		$53M Buy
5,869,076
+3,771,840
+180% +$30.2M 0.94% 32
2025
Q3 		$14.3M Buy
+2,097,236
New +$9.56M 0.41% 49
2024
Q3 		– Sell
-800,000
Closed -$7.54M – 113
2024
Q2 		$7.54M Sell
800,000
-198,888
-20% -$2.55M 0.18% 70
2024
Q1 		$16.9M Buy
+998,888
New +$12.2M 0.3% 66

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Perceptive Advisors's ENGN Position: Q2 2026 in Review

Perceptive Advisors reduced its enGene Therapeutics (ENGN) stake by 17% in Q2 2026, selling an estimated $4.1M and leaving 4,822,169 shares worth $8.34M. The position accounts for 0.13% of the portfolio, ranked #83.

Perceptive Advisors first reported a position in ENGN in Q1 2024 and has held it in 6 quarters since. The position peaked at $53M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Perceptive Advisors held 4,822,169 shares of enGene Therapeutics worth $8.34M as of Q2 2026.
  • Perceptive Advisors sold 1,005,337 enGene Therapeutics shares in Q2 2026, an estimated $4.1M.
  • enGene Therapeutics made up 0.13% of Perceptive Advisors's portfolio in Q2 2026, its #83 holding.
  • Perceptive Advisors first reported a position in enGene Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Perceptive Advisors's enGene Therapeutics position peaked at $53M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.